SOST

SOST

SOST Overview

Molecule Name
Sclerostin
Synonyms
SOST,VBCH
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs1
Highest Development StageApproved
Target Synonym
Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

SOST Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma Ag
Bone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
Details
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) Ltd
Osteogenesis Imperfecta
Details
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines Ltd
Osteoporosis; Osteoporosis, Postmenopausal
Details
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd
Osteoporosis; Osteoporosis, Postmenopausal
Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co Ltd
Osteoporosis, Postmenopausal
Details
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And Company
Osteoporosis; Osteoporosis, Postmenopausal
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08
Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
Details